Biotech · Private company
Fresenius Kabi
Track this companyFree. Adds Fresenius Kabi to your Dealase workspace and tells you when its record changes.
Clinical trials62 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- Intralipid® 20%Phase 3 · Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 DaysClinicalTrials.gov · fetched Nov 12, 2026
- Smoflipid 20% (investigational lipid for parenteral nutrition)Phase 3 · Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 DaysClinicalTrials.gov · fetched Nov 12, 2026
- Compounded standard parenteral nutritionMalnutritionClinicalTrials.gov · fetched Nov 12, 2026
- Intralipid, 20%Malnutrition, ChildClinicalTrials.gov · fetched Nov 12, 2026
- Kabiven®MalnutritionClinicalTrials.gov · fetched Nov 12, 2026
- Omegaven® (fish oil triglycerides) Injectable EmulsionParenteral Nutrition Associated Liver Disease (PNALD)ClinicalTrials.gov · fetched Nov 12, 2026
- SmoflipidMalnutrition, ChildClinicalTrials.gov · fetched Nov 12, 2026
- SMOFlipid® (lipid injectable emulsion)Malnutrition, ChildClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven TreatmentRECRUITING · started Dec 15, 2024ClinicalTrials.gov NCT06274788 · fetched Nov 12, 2026
- Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult PatientsPHASE4 · RECRUITING · started Oct 28, 2024ClinicalTrials.gov NCT06049680 · fetched Nov 12, 2026
- Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of AgePHASE4 · TERMINATED · started Dec 18, 2019ClinicalTrials.gov NCT03563222 · fetched Nov 12, 2026
- Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of AgePHASE4 · WITHDRAWN · started Mar 1, 2018ClinicalTrials.gov NCT03481894 · fetched Nov 12, 2026
- Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and InfantsPHASE3 · TERMINATED · started Dec 1, 2015ClinicalTrials.gov NCT02579265 · fetched Nov 12, 2026
- Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical PatientsPHASE3 · COMPLETED · started Mar 1, 2015ClinicalTrials.gov NCT02192502 · fetched Nov 12, 2026